Potential therapeutic medicines for renal fibrosis: Small-molecule compounds and natural products

Yu Xiang1, Zhuo Yuan2, Qichuan Deng1

  • 1Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.

Bioorganic Chemistry
|November 30, 2023
PubMed

Insights

Renal fibrosis, a key factor in chronic kidney disease progression, involves kidney cell damage and collagen deposition. This review explores potential therapeutic targets and natural products for treating this condition, aiming to prevent end-stage renal failure.

Area of Science:

  • Nephrology
  • Pathology
  • Pharmacology

Background:

  • Renal fibrosis is a progressive pathological process in chronic kidney disease (CKD).
  • It is characterized by intrinsic kidney cell damage, phenotypic changes, and excessive collagen deposition.
  • This leads to hardening of the renal parenchyma, impaired kidney function, and eventual end-stage renal failure (uremia).

Purpose of the Study:

  • To review the diagnosis, pathogenesis, and potential therapeutic inhibitors of renal fibrosis.
  • To discuss potential therapeutic targets and their inhibitors, including pharmacological effects and target interactions.
  • To summarize natural products with potential efficacy for renal fibrosis.

Main Methods:

  • Literature review of existing research on renal fibrosis.
  • Analysis of diagnostic criteria and pathogenic mechanisms.
  • Exploration of pharmacological data for potential therapeutic agents.

Main Results:

  • Renal fibrosis is a complex process driven by cellular damage and matrix accumulation.
  • Current therapeutic strategies lack specific targets and drugs for renal fibrosis.
  • Several potential targets and natural products show promise for managing renal fibrosis.

Conclusions:

  • Effective therapeutic targets and drugs for renal fibrosis are still under development.
  • Further research into pharmacological inhibitors and natural products is crucial.
  • This review provides insights for future therapeutic strategies against renal fibrosis.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
637
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.5K
Renal Drug Excretion: Tubular Secretion01:28

Renal Drug Excretion: Tubular Secretion

Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
192
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
170
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
396